SCHEMBL14224181

SCHEMBL14224181

CCOC(=O)N[C@@H]1CCNC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.47
EPHX1 P07099 4/20 0.41
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
GNAI3 P08754 1/20 0.40
GNAO1 P09471 1/20 0.40
GNAI1 P63096 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
HSD11B1 P28845 1/20 0.39
POLB P06746 1/20 0.38
KDM1A O60341 1/20 0.37
MAPK1 P28482 2/20 0.37
OPRK1 P41145 1/20 0.37
DRD2 P14416 1/20 0.36
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2426353 1.00 KCNH2 (0.47) KCNH2EPHX1MAPTPKMGNAI3
SCHEMBL14224187 1.00 KCNH2 (0.47) KCNH2EPHX1MAPTPKMGNAI3
Hydrochloric Acid SCHEMBL17560365 0.98 KCNH2 (0.46) KCNH2EPHX1MAPTPKMGNAI3
Hydrochloric Acid SCHEMBL17560364 0.98 KCNH2 (0.46) KCNH2EPHX1MAPTPKMGNAI3
Hydrochloric Acid SCHEMBL28954175 0.98 KCNH2 (0.46) KCNH2EPHX1MAPTPKMGNAI3
SCHEMBL965237 0.90 MAPK1 (0.47) KCNH2EPHX1NFKB1NFKB2RELA
SCHEMBL883979 0.89 EPHX1 (0.53) EPHX1GNAI3GNAO1GNAI1NFKB1
Hydrochloric Acid SCHEMBL10337608 0.88 EPHX1 (0.52) EPHX1MAPTPKMGNAI3GNAO1
SCHEMBL10442815 0.87 KCNH2 (0.44) KCNH2EPHX1GNAI3GNAO1GNAI1
SCHEMBL951710 0.84 GAA (0.50) KCNH2EPHX1GNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577211-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER Wake Forest University Health Sciences (US) 2025-07-02 EP disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed
CN-104918928-A Tricyclic compounds, their preparation and use ZAFGEN INC 2015-09-16 CN disclosed
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones PFIZER INC 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones MCHR1, MCHR2, MC1R KCNH2 3042/4885EPHX1 941/4885MAPT 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.